Tel Aviv (June 21, 2020) – BioLight is pleased to announce that its subsidiary, DiagnosTear Ltd. (“DiagnosTear“), that is engaged in research, development and commercialization of a product that is based on DiagnosTear’s TeaRx ™ technology, which is used today to diagnose, personalize treatment and monitor dry eye syndrome (“DES”) by examining the composition of the tear film (“DiagnosTear Product”), announced that it has signed an agreement with a leading global pharmaceuticals company and a leading eye research medical center in India (the “Agreement”). The purpose of the Agreement is performing a clinical trial for the DiagnosTear Product in the eye research medical center in India and examining, together with the global pharmaceuticals company, a potential commercial cooperation.
 Holding via XL Vision Sciences Ltd. (wholly owned subsidiary) approx. 89% of the issued and share capital of Diagnostear (approx. 86% fully diluted).Link to Newsroom